Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma

Potti, Anil; Willardson, James; Forseen, Caralee; Ganti, Apar Kishor; Koch, Michaël; Hebert, Brian; Levitt, Ralph; Mehdi, Syed

doi:10.1016/s0169-5002(01)00488-3

Cited by 43 publications

(39 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 39 studies, published between 1990 and 2002, were found eligible (Kern et al, 1990(Kern et al, , 1994Tateishi et al, 1991Tateishi et al, , 1994Volm et al, 1992Volm et al, , 1993aHarpole et al, 1995aHarpole et al, , b, 1996Giatromanolaki et al, 1996a, b;Pfeiffer et al, 1996;Koukouraki et al, 1997Koukouraki et al, , 2000MacKinnon et al, 1997;Pastorino et al, 1997;Visscher et al, 1997;Yu et al, 1997;Graziano et al, 1998;Greatens et al, 1998;Hsieh et al, 1998;Kim et al, 1998;Kwiatkowski et al, 1998;Nemunaitis et al, 1998;Cantero et al, 1999Cantero et al, , 2000D'Amico et al, 1999;Fu et al, 1999;Moldvay et al, 2000;Schneider et al, 2000;Ardizzoni et al, 2001;Brabender et al, 2001;Liao et al, 2001;Shou et al, 2001;Carbognani et al, 2002;Han et al, 2002;Hirsch et al, 2002;Potti et al, 2002;Selvaggi et al, 2002). Nine of the articles were excluded because identical cohorts of patients were used (studies that were excluded and included were, respectively, references (Cantero et al, 1999) and (Cantero et al, 2000), (Giatromanolaki et al, 1996b;…”

Section: Studies Selection and Characteristicsmentioning

confidence: 99%

The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature

et al. 2003

View full text Add to dashboard Cite

C-erbB-2 prognostic value for survival in patients with lung cancer remains controversial. We performed a systematic review of the literature to clarify its impact. Studies were identified by an electronic search in order to aggregate the survival results, after a methodological assessment using the scale of the European Lung Cancer Working Party. To be eligible, a study had to deal with cerbB-2 assessment in lung cancer patients and to analyse survival according to c-erbB-2 expression. In total, 30 studies were eligible: 24 studies dealt with non-small-cell lung carcinoma (NSCLC), five with adenocarcinoma and one study dealt with small-cell carcinoma. In all, 31% of the patients were positive for c-erbB-2. According to c-erbB-2 expression, 13 studies were 'negative' (significant detrimental effect on survival), one 'positive' (significant survival improvement) and 16 not significant. Significant studies had a better subscore relative to analysis and results report than nonsignificant studies. In total, 86% of the significant studies and only 56% of the nonsignificant studies were evaluable for the meta-analysis. This suggests a possible bias in our aggregated results. For NSCLC, the hazard ratio was 1.55 (95% CI: 1.29 -1.86) in favour of tumours that do not express c-erbB-2. In conclusion, the overexpression of c-erbB-2 might be a factor of poor prognosis for survival in NSCLC, but there is a potential bias in favour of the significant studies with an overestimation risk of the magnitude of the true effect of c-erbB-2 overexpression.

show abstract

Section: Studies Selection and Characteristicsmentioning

confidence: 99%

The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature

et al. 2003

View full text Add to dashboard Cite

show abstract

“…HER2/neu expression in SCLC has been less well studied. Studies have demonstrated overexpression of HER2/neu by immunohistochemistry in approximately 13-30% of patients with advanced stage SCLC (Micke et al, 2001;Potti et al, 2002. These studies also found that HER2/neu expression was associated with a poor prognosis for patients with advanced disease.…”

Section: Epidermal Growth Factor Receptor (Egfr)mentioning

confidence: 88%

Oncogenes and Tumor Suppressor Genes in Small Cell Lung Carcinoma

Taneja¹,

Kendig²,

Zhu³

et al. 2012

Lung Diseases - Selected State of the Art Reviews

View full text Add to dashboard Cite

“…Some studies have identified HER2 expression as a negative prognostic factor of SCLC, especially in extensive diseases in Caucasians (15,16). HER2 overexpression has been reported to be about 10% to 30% in Western patients with SCLC (17) and 10% (1 of 11) of SCLC cell lines established from Caucasian patients (33).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, like EGFR-TKIs, lapatinib has also been reported to inhibit the functions of ABC transporters in breast cancer cells (14). In SCLC, HER2 expression is also reported to be an independent negative prognostic factor of extensive disease (15)(16)(17). However, no studies have yet been conducted to assess whether HER2 can be a therapeutic target in SCLC.…”

Section: Introductionmentioning

confidence: 99%

HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter–Mediated Chemoresistance in Small Cell Lung Cancer

Minami

Kijima

Otani

et al. 2012

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) easily acquires multidrug resistance after successful initial therapy. Overexpression of ATP-binding cassette (ABC) transporters is important for the multidrug resistance. Among them, ABCB1 and ABCG2 are known to be upregulated in chemoresistant SCLC cells. We found that human epidermal growth factor receptor 2 (HER2) expressions are also upregulated in chemoresistant SBC-3/ETP, SBC-3/SN-38, and SBC-3/CDDP cells, compared with chemosensitive SBC-3 cells. Lapatinib, a tyrosine kinase inhibitor of HER2, could not suppress proliferation of these HER2-positive SCLC cells alone but successfully restored chemosensitivity to etoposide and SN-38 with a clinically applicable concentration. The reversal effect of lapatinib was thought to be caused by inhibition of drug efflux pump functions of ABC transporters, although lapatinib itself has been reported to be a substrate for them. Moreover, knocking down of HER2 by an short interfering RNA weakened the effect of lapatinib on ABCB1, indicating the involvement of HER2 in the inhibitory mechanisms. Notably, we showed that caveolin-1 and Src play key roles in modulating ABCB1 function via HER2 inactivation. In SBC-3/ETP cells, dephosphorylation of HER2 by lapatinib activates Src and successively leads to increased caveolin-1 phosphorylation. Through this process, caveolin-1 dissociates from HER2 and strengthens association with ABCB1, and finally impairs the pump functions. Furthermore, we showed that treatment by lapatinib in combination with etoposide or irinotecan significantly suppresses the growth of subcutaneous SBC-3/ETP and SBC-3/SN-38 tumors in mice, respectively. Collectively, these results indicate that combination therapy with lapatinib and cytotoxic agents could conquer ABC transportermediated chemoresistance especially in HER2-positive SCLC. Mol Cancer Ther; 11(4); 830-41. Ó2012 AACR.

show abstract

Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma

Cited by 43 publications

References 28 publications

The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature

The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature

Oncogenes and Tumor Suppressor Genes in Small Cell Lung Carcinoma

HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter–Mediated Chemoresistance in Small Cell Lung Cancer

Contact Info

Product

Resources

About